Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Heppner, Oregon Health and Science University, USA
Clinical Results and Benefits In the ACHIEVE-3 trial, Orforglipron demonstrated strong results in patients with type 2 diabetes: Hemoglobin A1C reduction of approximately 2.2% Average weight loss of 9.2% (around 20 pounds) Superior outcomes compared to oral semaglutide Additional studies also showed improvements in cardiovascular risk factors, including reductions in LDL cholesterol, triglycerides, and inflammatory markers like C-reactive protein
Fiber comes next
Speak to a healthcare provider if you experience these symptoms regularly
Convenient, cost-effective, optimal ratio
US$ 25.89
US$ 22.46
US$ 22.98
US$ 21.86
US$ 22.89
US$ 24.76
US$ 22.79
US$ 20.94
US$ 28.64
